Open Actively Recruiting

Basimglurant in Children, Adolescents, and Young Adults With TSC

About

Brief Summary

The study intends to show that basimglurant provides effective seizure control in children, adolescents and young adults with Tuberous Sclerosis Complex (TSC).

Primary Purpose
Treatment
Study Type
Interventional
Phase
Phase 2

Eligibility

Gender
All
Healthy Volunteers
No
Minimum Age
5 Years
Maximum Age
30 Years

Inclusion Criteria (summary):

  • Ability and willingness to provide informed assent or written consent or consent from their legal representative.
  • Fluency in the language of the study staff
  • Age 5 to 30 years at study entry
  • A documented history of TSC
  • Refractory seizure history
  • Currently receiving one or more anti-epileptic drugs (AEDs)
  • Stable medications or interventions for epilepsy
  • Willingness to complete Patient Reported Outcome assessments
  • For female patients of childbearing potential:
    • Willingness to undergo serum or urinary pregnancy testing at screening and during the trial period.
    • Willingness to use contraception.

Exclusion Criteria (summary):

  • Neurologic disease other than TSC
  • Recent anoxic episode
  • Patient weight below 15kg
  • Clinically significant unstable medical condition(s)
  • Pregnancy or lactation

Join this Trial

Contact our clinical trial navigators for opportunities that may be suitable for you
Share:
Study Stats
Protocol No.
21-001187
Category
Brain/Neurological Diseases
Genetic and Rare Diseases
Pediatric and Prenatal Disorders
Contact
Angela Martinez
Location
  • UCLA Westwood
For Providers
NCT No.
NCT05059327
For detailed technical eligibility, visit ClinicalTrials.gov.